Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Explore the available resources

Click the videos below to watch members of the SMA community discuss the latest topics of interest.
Evrysdi Tablet Dosage Form
Dr James Lilleker shares how the Evrysdi tablet formulation could impact people with SMA
Pre symptomatic Evrysdi
Professor Laurent Servais presents the latest data for Evrysdi in infants with presymptomatic SMA
Pre symptomatic Population Screening
Our panel of experts discuss the RAINBOWFISH 2-year analysis and the role of newborn screening
Systemic administration SMN complex
Gain a deeper understanding of SMA as a multi-systemic disease

SMA Exchange is a Roche-owned educational meeting for UK healthcare professionals and allied health professionals, with an interest in SMA, held in June 2024.

References

1. Evrysdi 5 mg film‑coated tablets Summary of Product Characteristics

2. Evrysdi 0.75 mg/mL powder for oral solution Summary of Product Characteristics
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.